Albireo Pharma‘s patent involves 1,5-benzothiazepine and 1,2,5-benzothiadiazepine derivatives as bile acid modulators for treating cardiovascular, metabolic, gastrointestinal, and liver diseases. The method includes administering the compound to a subject. GlobalData’s report on Albireo Pharma gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Albireo Pharma, was a key innovation area identified from patents. Albireo Pharma's grant share as of February 2024 was 57%. Grant share is based on the ratio of number of grants to total number of patents.
A recently granted patent (Publication Number: US11891368B2) discloses a method for treating various diseases and disorders in a subject by administering a therapeutically effective amount of a compound of formula (I). The diseases and disorders that can be targeted using this method include cardiovascular diseases, disorders of fatty acid metabolism, glucose utilization disorders, gastrointestinal diseases, and liver diseases. Specific examples of conditions that fall under these categories include hypercholesterolemia, diabetes mellitus, obesity, Crohn's disease, primary bile acid malabsorption, and various liver disorders such as biliary atresia, autoimmune hepatitis, and non-alcoholic fatty liver disease.
The patent further details the specific compounds that can be used in the treatment method, including various derivatives of benzothiazepin and benzothiadiazepin. These compounds have shown potential in addressing a wide range of diseases and disorders, particularly those related to metabolic and gastrointestinal health. By targeting specific pathways and mechanisms associated with these conditions, the compounds offer a promising approach to managing and treating complex medical issues. The patent provides a comprehensive list of compounds that can be utilized, highlighting the versatility and potential applications of this innovative treatment method in addressing a diverse array of health concerns.
To know more about GlobalData’s detailed insights on Albireo Pharma, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
